Author: [AUTHOR] Published on 6/1/2023 12:00:00 AM
Jing Liu, PhD, Senior Director, Clinical Pharmacology, Pfizer, Niantic, CT
What are you looking forward to about serving on the Board of Directors?
I am humbled and honored to serve on the ASCPT Board of Directors. I'm looking forward to working with the new ASCPT leadership and fellow Board members to build upon the great success of previous leadership, further advance the ASCPT Strategic Plan, continuously establish ASCPT as the leading organization in the field of clinical pharmacology, therapeutics, and translational science, and create an inclusive professional home for our diverse ASCPT members.
What professional accomplishment are you most proud of?
My proudest professional accomplishment is not a single moment, but that I have contributed to the movement of MIDD across the continuum of selecting the right pathway, the right target, the right compound, the right dose, and the right patients. I have been very fortunate to work with supportive leaders, talented colleagues, and collaborators who share the same passion along the way. I am also very grateful for the volunteering leadership opportunities from ASCPT and IQ Consortium, which have allowed me to influence the broader communities. I look forward to continuing this journey and advancing innovations in my new role.
Who has inspired you in your career?
I have been privileged to have the opportunity to interact with many world-class leaders and inspirational mentors. If I must pick one, I'd say Rick Lalonde, PharmD. Rick has inspired me through his revolutionary vision in model-based/informed efficient drug development and rational decision, his relentless effort in expanding the scope of MIDD influence, and most importantly, his authentic leadership, humility, and kindness. Rick has been a major mentor and role model for me.
What is your favorite society memory?
I have many treasured memories of my engagement with ASCPT. I vividly remember the first workshop I co-chaired at ASCPT 2008 with Piet van der Graaf, PharmD, PhD, on Mechanism-Based PK/PD Modeling and Simulation as the Basis for Translational Research and Optimal Clinical Trial Design. Even though it was scheduled on the last half day of the conference on a sunny Saturday in Orlando, FL, the workshop was filled to the point of standing-room-only. I have always enjoyed attending the Annual Meeting to learn from and network with other members and to serve as a mentor. I also fully appreciate all the volunteer experience within ASCPT such as serving on various committees and as a Community and Network Leader and the collaboration and friendship with ASCPT Staff. I especially cherish the opportunity of working with Anu Ramamoorthy, PhD, when we were DRO Network leaders. It is rewarding to see that DRO has grown to a much larger, more defined, and is now a more diverse Network. More recently, co-leading the cross-Network collaboration on advancing RWD/RWE with Karen Yeo, PhD, Paulien Ravenstijn, PhD, and IQ RWE Workgroup has also been very fulfilling. While this initiative has brought the Networks closer and fostered external collaboration, it will also help to advance the broader application of RWD/RWE in clinical pharmacology and translational research.
When you are not working, how do you spend your free time?
I enjoy walking/jogging on the beach with my family and friends, to take advantage of my proximity to the beach. Occasionally, I put my creative skills toward inventing new East-meets-West recipes. Since the pandemic, I have started gardening and cannot wait to start the new season.
Jing has been a member of ASCPT since 2003.
